Zeev Estrov, MD, professor of medicine, MD Anderson Cancer Center, discusses questions that still need to be answered in the myelofibrosis field.
Nivolumab/Ipilimumab Plus Chemotherapy as Frontline Therapy Shows Continued Efficacy in mNSCLC
June 5th 2023Data from CheckMate 9LA trial further support the use of nivolumab plus ipilimumab and chemotherapy as an efficacious first-line treatment option for patients with metastatic NSCLC, says David P. Carbone, MD, PhD.
Read More
Elacestrant Shows Survival Benefit in Certain ER+/HER2- Advanced Breast Cancer
June 4th 2023A subgroup analysis from the EMERALD trial reveals that elacestrant prolonged progression free survival for certain patients with estrogen receptor-positive HER2-negative non-detected shortly after progression on CDK3/6 inhibitors.
Read More
Following Prior Immunotherapy Resistance in Advanced PD-L1+ NSCLC Rilvegostomig Shows Promise
June 4th 2023Preliminary results from the phase 1/2 ARTEMIDE-01 trial show the potential for PD-1 and TIGIT bispecific agent rilvegostomig in patients with advanced or metastatic PD-L1–positive non–small cell lung cancer.
Read More
2 Clarke Drive
Cranbury, NJ 08512